Aminoglycosides are one of the clinically relevant antibiotics. They kill bacteria by binding to bacterial 30S subunit of ribosome. Resistance to aminoglycosides occurs by three different mechanisms: 1. Production of an enzyme that modifies aminoglycosides, 2. Impaired entry of aminoglycoside into the cell by altering the OMP permeability, decreasing inner membrane transport, or active efflux, 3. The receptor protein on the 30S ribosomal subunit may be deleted or altered as a result of a mutation. By far, enzymatic modification has been the most important mechanism. In this review, the mechanisms of action and resistance, and the prevalence of resistance due to acquisition of enzymes are briefly described. 
The aminoglycosides/aminocyclitol antibiotics are characterized by two or more amino sugars linked by a glycosidic bond to the aminocyclitol (hexose) ring, which is either streptidine (found in streptomycin) or 2-deoxystreptamine (found in other aminoglycosides) ( Aminoglycoside resistance mechanisms can be ascertained by examining the susceptibility of the strains to a panel of aminoglycosides (phenotypic characterization) ( Table 1 ) [4] . However, in case of harboring more than two enzymes, the phenotype will not match any one of them. This enzyme is important because it confers resistance to amikacin, netilmicin, kanamycin, and tobramycin and its gene is located within integrons and transposons [5, 6] .
In Korean isolates of AmpC-producing Enterobacteriaceae, the prevalence of aac(6')-Ib was 41.3%, 18.7%, and 6.6%, respectively in Enterobacter cloacae, Citrobacter freundii and Serratia marcescens [6] . Interestingly, of the aac(6')-Ib or aac(6')-Ib-cr harboring isolates, only about only 25∼30% were nonsusceptible to amikacin [6, 7] and this finding needs further investigation. Moreoever, the fact that AAC(6')-I coexists very frequently with other antibiotic-inactivating enzymes such as β-lactamases, carbapenemases or other aminoglycosidases alarms us [7] .
For P. aeruginosa, Miller et al. [8] brought together several studies carried out worldwide. Results showed that in Europe, between 1988 and 1993, aac(6')-II was the most prevalent (2.1 ∼70.3%, avr. 32.5%), followed by ant(2'')-I (1.7∼45.2%, avr.
16.9%), and non-enzymatic resistance (4.3∼23.7%, average of 14.0%). In a study conducted with P. aeruginosa isolates showing high-level resistance to gentamicin and netilmicin and strains presenting a low-level resistance to all aminoglycosides including apramycin, collected in 2000 from community and private healthcare centers [9] , the predominance of the three enzymes (aac(6')-Ib, ant(2'')-Ia, aac(3)-IIc) was observed (36.5%, 21.2%, and 7.7%, respectively), and the non-enzymatic resistance was 34.6%. In addition, the presence of aac(6')-Ib, which acetylates kanamycin, tobramycin, netilmicin, amikacin (KTNA), but not gentamicin, was regularly associated with a decreased gentamicin susceptibility. And it was assigned to the amino acid sequence at position 119, a leucine being associated with amikacin resistance and a serine with gentamicin resistance.
In Korean nationwide study, of the 250 isolates of P. aerugi- Table 1 . Phenotypic characteristics of isolates producing aminoglycoside modifying enzymes (cited from EUCAST expert rules in antimicrobial susceptibility testing)
Abbreviations: S, streptomycin; Sp, spectinomycin; K, kanamycin; A, amikacin; G, gentamicin; Nt, netilmicin; T, tobramycin; Nm, neomycin; APH, aminoglycoside phosphotransferase; ANT, aminoglycoside nucleotidyltransferase; AAC, aminoglycoside acetyltransferase; R, resistance; r, reduced zones but likely to remain susceptible at BSAC breakpoints; S, susceptible.
nosa collected in 2002, the amikacin resistance rate was 22%
(55 isolates), and of them, aph(3')-VI, ant(2'')-I, and aac(6')-I were found in 37, 32, and 18 isolates, respectively, alone or in combination [10] . Thirty-six strains harboured two or more types of enzymes, of which a combination of aac(6')-I and ant(2'')-I was the most frequent (24/36 isolates). The association with class 1 integron was confirmed with all of the ant(2'')-I, 6 of 18 aac(6')-I, but none of the aph(3')-VI. The difference in the enzyme distribution might be derived from the difference in selection of bacterial population and aminoglycoside usage.
More recently, 16S rRNA methylases (RmtA, RmtB, RmtC, RmtD, ArmA and NpmA) conferring resistance to almost all aminoglycosides, including arbekacin, has emerged and disseminated via mobile elements. Of these, armA gene has been found to be widely disseminated among various species [11] , and was found on a large plasmid which carries a type 1 integron that mediates various gene cassettes responsible for multiple antimicrobial resistance [12] . In Korean isolates of Enterobacteriacae at a university hospital, armA was first appeared in 1997 [13] .
Among the E. cloacae, C. freundii, and S. marcescens collected in 2003, amikacin resistance rate was 9.5%, 10.3% and 17.1%, respectively. About 84.5% of the amikacin-resistant isolates showed high-level (MIC＞512μg/mL), and almost all of them harboured armA gene [14] . Among arbekacin or amikacin-nonsusceptible K. pneumoniae and A. baumannii, 53.8% and 53.3%
harbored armA, respectively, and most armA-harboring A. baumannii were nonsusceptible to carbapenem [15] .
rmtA gene is likely associated with the mercury-resistant transposon Tn5041 [16] ; the rmtB gene was found in the flanking region of Tn3-like structure [17] . The rmtC was located downstream of an ISEcpI-like element containing tnpA [18] .
NpmA is unique in that it gives resistance to apramycin and neomycin, due to methylation of the A1408 position at the A site of 16S rRNA; all other 16S rRNA methylases methylate the G1405 position [19] .
Aminoglycosides is also the substrates for a number of multidrug efflux pumps, including the resistance nodulation cell division (RND) transporter superfamily, which plays an important role in Gram-negative bacteria. Several RND proteins are involved in aminoglycoside resistance in various Gram-negative pathogens, including P. aeruginosa, Burkholderia pseudomallei, Acinetobacter baumannii, and E. coli [20] .
Despite these various resistance mechanisms, aminoglycosides are still valuable weapons in antimicrobial treatment, particularly in the treatment of serious Gram-negative nosocomial infections [5] . To use the aminoglycosides properly, accurate detection of resistance and efforts to prevent the spread of resistant isolates are required. 
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